Archives — Current Month (13)
Biopharma Agrees to $215 Million Acquisition Deal (11/21/2018)
An H.C. Wainwright & Co. report detailed the terms of the definitive agreement concerning the merger.
The change relates to the onset of dosing for patients with different degrees of disease.
A distributor of the proprietary product places a third large order.
This firm's proprietary technology provides an alternative to antibiotic use in livestock production.
With this development, the company advances blood/plasma transfusion technology.
Imprimis: Priming the Pumps for a Big 2019 (11/15/2018)
Daniel Carlson of Tailwinds Research profiles a biotech company he is bullish on.
An H.C. Wainwright & Co. report highlighted this biotech's upcoming key events to watch.
A ROTH Capital Partners report relayed the contents of both presented abstracts.
An H.C. Wainwright & Co. report discussed what investors might expect to hear from the company regarding its cholesterol-lowering therapy.
A LifeSci Capital report highlighted the advantages of this biotech story's lead candidate targeting bladder cancer.
This firm explains how its 15 years in drug development led to and supports this conclusion.
Fincom Investment Partners takes a look at Q3 earnings for a U.S.-based CBD company and explains why it believes it offers good value.
A Canadian Cannabis Company for the Next Wave (11/06/2018)
Ron Struthers, who believes the ideal marijuana stock to buy at this time is one that is focused on cannabis oil, profiles one such company that he sees as undervalued.
|"VIVs recent distribution deals illustrate demand for its technology."|
|"PMN is looking to outlicense PMN310 after the Phase 1 study."|
|"DRRX intends to start a NASH trial as soon as H1/19."|